NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn’s disease: A preliminary report.

Barreiro-de Acosta M, Ouburg S, Morre SA, Crusius JBA,Lorenzo A, Potel J, Pena AS, Enrique Dominguez-Munoz J.
Rev Esp Enferm Digest 2010; 102(10):591-5.